drugset / Trial / NCT03652467

The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

NCT03652467

Phase 1 Unknown 100 enrolled Jinan Military General Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).

Timeline

Start
2018-09-01
Primary completion
2022-09-01
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferoxamine Other / unclassified